Slc17A7 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The SLC17A7 gene (Solute Carrier Family 17 Member 7), also known as VGLUT2 (Vesicular Glutamate Transporter 2), encodes a vesicular glutamate transporter expressed primarily in thalamocortical neurons and subpopulations of cortical and hippocampal neurons. VGLUT2 plays a crucial role in glutamate neurotransmission and has been linked to several neurodegenerative and neurodevelopmental disorders.
| Attribute | Value |
|-----------|-------|
| Gene Symbol | SLC17A7 |
| Full Name | Solute Carrier Family 17 Member 7 |
| Chromosomal Location | 19q13.33 |
| NCBI Gene ID | 8703 |
| Ensembl ID | ENSG00000177508 |
| UniProt ID | Q9P2U8 |
¶ Protein Structure and Function
The VGLUT2 protein is a member of the SLC17 anion transporter family and contains 12 transmembrane helices that form the translocation pore. It operates as a proton-dependent symporter that concentrates glutamate in synaptic vesicles.
- Vesicular Glutamate Transport: Packages glutamate into synaptic vesicles with high capacity
- Thalamocortical Transmission: Essential for sensory information relay from thalamus to cortex
- Synaptic Vesicle Cycling: Facilitates vesicle filling, storage, and activity-dependent release
- Quantal Size Determination: Controls the amount of glutamate per synaptic vesicle
VGLUT2 exhibits a distinct expression pattern compared to VGLUT1:
- Thalamus (all relay nuclei)
- Cerebral Cortex (layer IV spiny stellate cells)
- Hippocampus (CA3 pyramidal cells)
- Substantia Nigra pars reticulata
- Superior Colliculus
- Brainstem sensory nuclei
- VGLUT2 dysregulation in early AD stages
- Reduced thalamocortical glutamate transmission
- Contributes to sensory processing deficits
- Altered VGLUT2 in the basal ganglia output nuclei[^5]
- Impacts glutamatergic overactivity in PD pathophysiology
- Potential target for motor circuit modulation
- VGLUT2 mutations linked to ASD[^6]
- Affects thalamocortical connectivity
- Contributes to sensory processing differences
- VGLUT2 expression changes in epileptogenic tissue[^7]
- Dysregulation of thalamocortical excitability
- Target for anti-seizure drug development
- VGLUT2 Enhancers: Restore thalamocortical transmission in AD
- VGLUT2 Modulators: Normalize glutamate release in epilepsy
- Gene Therapy: AAV-VGLUT2 delivery to restore function
- CSF VGLUT2 as marker of thalamocortical integrity
- Brain VGLUT2 imaging with PET ligands
- Understanding VGLUT2 in sensory processing disorders
- Developing selective VGLUT2 modulators
- Investigating VGLUT2 gene variants in neuropsychiatric conditions
- VGLUT2 as therapeutic target in thalamic disorders
- VGLUT2-Cre mice: Used for optogenetic manipulation of thalamocortical neurons
- Conditional knockouts: Reveal region-specific functions
- Humanized mouse models: Study VGLUT2 mutations
The study of Slc17A7 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.